HealthCare Global Enterprises Ltd. (IN:HCG)
:HCG
Want to see IN:HCG full AI Analyst Report?
HCG Stock Chart & Stats
₹655.45
-₹2.50(-0.51%)
At close: 4:00 PM EST
₹655.45
-₹2.50(-0.51%)
Day’s Range― - ―
52-Week Range₹511.83 - ₹799.36
Previous CloseN/A
Volume91.36K
Average Volume (3M)18.12K
Market Cap
₹90.93B
Enterprise Value₹105.55B
Total Cash (Recent Filing)₹2.02B
Total Debt (Recent Filing)₹17.68B
Price to Earnings (P/E)646.3
Beta0.48
Next Earnings
Aug 06, 2026EPS Estimate
2.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.53
Shares Outstanding149,302,200
10 Day Avg. Volume16,611
30 Day Avg. Volume18,118
Financial Highlights & Ratios
PEG Ratio-7.78
Price to Book (P/B)5.59
Price to Sales (P/S)2.93
P/FCF Ratio135.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.53
Revenue Forecast (FY)₹29.20B
Bulls Say, Bears Say
Bulls Say
Oncology-focused Hospital NetworkA dedicated oncology hospital network creates durable specialization benefits: concentrated clinical expertise, referral economies, and integrated diagnostic/treatment services. This structural positioning supports stable demand, deeper patient relationships and higher barriers to entry versus generalist providers.
Strong Operating Cash GenerationConsistent growth in operating cash flow and positive free cash flow provide lasting ability to service debt, fund maintenance capex and support reinvestment into clinical capabilities. Reliable cash conversion underpins financial flexibility despite capital intensity of hospitals.
Equity Build Boosting ResilienceA meaningful equity increase materially strengthens the capital base, lowering net leverage and improving capacity to absorb shocks. For a capital-intensive care provider, stronger equity supports borrowing capacity, long-term investment and reduces refinancing risk over multiple quarters.
Bears Say
High LeverageElevated and rising debt leaves earnings exposed to interest cost swings and limits strategic flexibility. For hospitals with steady capex needs, high leverage raises refinancing and covenant risks and makes profitability highly sensitive to operating volatility and reimbursement changes.
Thin And Weakening Net MarginsNet margins compressed to near-zero, reducing internal accruals and the firm’s ability to self-fund growth. Persistently thin profitability amplifies the impact of any cost, reimbursement or financing pressure and constrains retained earnings buildup over multiple reporting periods.
Decelerating Revenue GrowthSlowing top-line expansion reduces scope to leverage fixed costs and hurts margin recovery prospects. If revenue momentum remains muted, the company will face tougher trade-offs between pricing, utilization and capital deployment to restore historical mid-teens growth rates.
HealthCare Global Enterprises Ltd. News
HCG FAQ
What was HealthCare Global Enterprises Ltd.’s price range in the past 12 months?
HealthCare Global Enterprises Ltd. lowest stock price was ₹511.83 and its highest was ₹799.36 in the past 12 months.
What is HealthCare Global Enterprises Ltd.’s market cap?
HealthCare Global Enterprises Ltd.’s market cap is ₹90.93B.
When is HealthCare Global Enterprises Ltd.’s upcoming earnings report date?
HealthCare Global Enterprises Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were HealthCare Global Enterprises Ltd.’s earnings last quarter?
HealthCare Global Enterprises Ltd. released its earnings results on May 19, 2026. The company reported ₹0.15 earnings per share for the quarter, missing the consensus estimate of ₹1.501 by -₹1.351.
Is HealthCare Global Enterprises Ltd. overvalued?
According to Wall Street analysts HealthCare Global Enterprises Ltd.’s price is currently Overvalued.
Does HealthCare Global Enterprises Ltd. pay dividends?
HealthCare Global Enterprises Ltd. does not currently pay dividends.
What is HealthCare Global Enterprises Ltd.’s EPS estimate?
HealthCare Global Enterprises Ltd.’s EPS estimate is 2.68.
How many shares outstanding does HealthCare Global Enterprises Ltd. have?
HealthCare Global Enterprises Ltd. has 149,302,200 shares outstanding.
What happened to HealthCare Global Enterprises Ltd.’s price movement after its last earnings report?
HealthCare Global Enterprises Ltd. reported an EPS of ₹0.15 in its last earnings report, missing expectations of ₹1.501. Following the earnings report the stock price went up 2.269%.
Which hedge fund is a major shareholder of HealthCare Global Enterprises Ltd.?
Currently, no hedge funds are holding shares in IN:HCG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HealthCare Global Enterprises Ltd.
HealthCare Global Enterprises Limited, founded in 1989 and headquartered in Bengaluru, India, delivers comprehensive healthcare services with a primary focus on oncology. The company offers a full spectrum of cancer care, from diagnosis to various treatment modalities such as radiation therapy, medical oncology, and surgical procedures. Beyond its core cancer services, HCG also operates in the field of fertility and reproductive medicine under its Milann brand. This includes services like assisted reproduction, gynecological endoscopy, and fertility preservation. The enterprise further manages four multi-specialty hospitals: three branded HCG facilities located in Ahmedabad, Bhavnagar, and Rajkot in Gujarat, and one in Hubli, Karnataka, operated under a management contract. These hospitals cater to diverse medical specialities including cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, pulmonary care, and critical care. Additionally, HealthCare Global provides medical diagnostic services, offering scientific testing and consultancy for the pharmaceutical and broader medical industries. As of March 31, 2021, its extensive network comprised 23 cancer centers throughout India, featuring a center of excellence in Bengaluru, alongside two independent diagnostic centers and one day-care chemotherapy unit. The company also maintains an international presence with a cancer center established in Africa.
Technical Analysis
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―
Narayana Hrudayalaya Ltd.
―